Banque Transatlantique SA Cuts Stock Position in Stryker Corporation $SYK

Key Points

• Banque Transatlantique SA has reduced its position in Stryker Corporation by 7.3%, now holding 115,927 shares valued at approximately $39.88 million.
• Several analysts have set target prices for Stryker, with Truist Financial at $415.00 and Needham & Company at $448.00, reflecting a generally positive outlook.
• Stryker recently announced a quarterly dividend of $0.84 per share, with an expected payout on October 31st, representing an annual yield of 0.9%.

Banque Transatlantique SA decreased its holdings in shares of Stryker Corporation (NYSE:SYK - Free Report) by 7.3% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 115,927 shares of the medical technology company's stock after selling 9,158 shares during the quarter. Stryker comprises approximately 0.7% of Banque Transatlantique SA's holdings, making the stock its 26th biggest holding. Banque Transatlantique SA's holdings in Stryker were worth $39,880,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the stock. Brighton Jones LLC grew its position in Stryker by 15.4% in the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock valued at $1,643,000 after acquiring an additional 609 shares in the last quarter. Baker Avenue Asset Management LP grew its holdings in Stryker by 3.6% during the 4th quarter. Baker Avenue Asset Management LP now owns 1,820 shares of the medical technology company's stock valued at $655,000 after purchasing an additional 63 shares in the last quarter. Cary Street Partners Financial LLC acquired a new stake in Stryker during the 4th quarter valued at $3,030,000. Captrust Financial Advisors increased its stake in Stryker by 0.9% during the 4th quarter. Captrust Financial Advisors now owns 36,272 shares of the medical technology company's stock worth $13,060,000 after buying an additional 308 shares during the period. Finally, Cetera Investment Advisers lifted its holdings in Stryker by 0.6% in the 4th quarter. Cetera Investment Advisers now owns 92,351 shares of the medical technology company's stock worth $33,251,000 after buying an additional 584 shares in the last quarter. 77.09% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on SYK shares. Truist Financial set a $415.00 target price on Stryker and gave the company a "hold" rating in a research note on Monday, August 4th. Needham & Company LLC upped their target price on Stryker from $442.00 to $448.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Wall Street Zen upgraded Stryker from a "hold" rating to a "buy" rating in a research note on Friday, July 18th. Citigroup reissued a "buy" rating and issued a $455.00 target price (up previously from $443.00) on shares of Stryker in a research report on Thursday, May 22nd. Finally, Wells Fargo & Company upped their target price on shares of Stryker from $435.00 to $445.00 and gave the company an "overweight" rating in a research note on Friday, August 1st. Fifteen analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $430.10.

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the sale, the director owned 3,222,108 shares of the company's stock, valued at $1,212,962,556.60. The trade was a 5.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Viju Menon sold 500 shares of the stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider directly owned 12,511 shares of the company's stock, valued at approximately $4,886,921.71. The trade was a 3.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is currently owned by company insiders.

Stryker Trading Down 0.5%

Shares of NYSE SYK opened at $389.65 on Wednesday. The company has a market cap of $148.97 billion, a price-to-earnings ratio of 51.61, a price-to-earnings-growth ratio of 2.85 and a beta of 0.93. The stock's 50 day simple moving average is $389.57 and its 200 day simple moving average is $379.45. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last issued its earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.07 by $0.06. The firm had revenue of $6.02 billion for the quarter, compared to analyst estimates of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm's revenue for the quarter was up 11.1% on a year-over-year basis. During the same period last year, the company earned $2.81 earnings per share. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. Equities research analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Shareholders of record on Tuesday, September 30th will be given a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a yield of 0.9%. Stryker's dividend payout ratio is 44.50%.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.